InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,618.80
(
0.05%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.62
(
-0.30%
)
Bitcoin
62,516.81
(
0.28%
)
Post# of 30990
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

knuts4oe

Send PM Follow Ignore
Followers 4
Posts 682
Boards Moderated 0
Alias Born 06/26/2013

knuts4oe

Re: NukeJohn post# 20545

Tuesday, 09/02/2014 5:21:55 PM

Tuesday, September 02, 2014 5:21:55 PM

Post# of 30990
Very much surprised that there has been little comment about Dr Alex Roher's contribution to this study. His resume is comparable to Dr Mullan's, and his 20 year focus has been on AD and PD. Interesting that he would choose to take part in a study of the mechanism of action of anatabine, since he has not had any previous involvement with it as far as I can determine.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up